Clinical Trial: Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients

U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934252) titled 'Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients' on April 11.

Brief Summary: This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD).

Part 1 (SAD): Healthy participants receiving single doses or placebo. Part 2 (MAD): Healthy participants receiving multiple doses (3 doses over 8 weeks) of TRB-061 or placebo.

Part 3 (MAD+): Participants with moderate-to-severe AD receiving repeated doses (4 doses...